SCHEMBL28830319

SCHEMBL28830319

CC(C)(C)NC(=O)O[C@@H]1CCN(c2cc(Cl)cc(N3CCOCC3)n2)C1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ POLB P06746 2/20 0.38
▸ RAF1 P04049 1/20 0.38
▸ BRAF P15056 1/20 0.38
▸ LMNA P02545 1/20 0.37
▸ KMT2A Q03164 3/20 0.37
▸ KIF18A Q8NI77 2/20 0.37
▸ AKT1 P31749 7/20 0.36
▸ PIK3CB P42338 5/20 0.36
▸ PIK3CD O00329 4/20 0.36
▸ PIK3CA P42336 2/20 0.36
▸ PIK3CG P48736 2/20 0.36
▸ CYP3A4 P08684 2/20 0.36
▸ MCHR1 Q99705 1/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28830325 0.83 RAF1 (0.38) CYP1A2CYP2D6MAPTPOLBRAF1
SCHEMBL28830297 0.83 CYP1A2 (0.43) CYP1A2CYP2D6MAPTPOLBLMNA
SCHEMBL29762501 0.79 GAA (0.41) CYP1A2CYP2D6MAPTRAF1BRAF
SCHEMBL23275378 0.79 GAA (0.41) CYP1A2CYP2D6MAPTRAF1BRAF
SCHEMBL23299990 0.79 GAA (0.41) CYP1A2CYP2D6MAPTRAF1BRAF
SCHEMBL8787610 0.77 LMNA (0.36) LMNAMCHR1
SCHEMBL23274606 0.76 RAF1 (0.46) CYP1A2CYP2D6MAPTPOLBRAF1
SCHEMBL29762401 0.76 RAF1 (0.46) CYP1A2CYP2D6MAPTPOLBRAF1
SCHEMBL23275320 0.75 MAPT (0.40) CYP1A2CYP2D6MAPTPOLBRAF1
SCHEMBL23275324 0.75 MAPT (0.40) CYP1A2CYP2D6MAPTPOLBRAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114845711-A Inhibitors of RAF kinase 金耐特生物制药公司 2022-08-02 — — CN disclosed
Send feedback